Erik Noeldekehollmann

Erik Noeldeke-Hollmann currently serves as the Business Development Manager for the EU/Europe at Advaxia Biologics, where he plays a pivotal role in driving strategic growth and fostering collaborative partnerships within the biopharmaceutical landscape. Leveraging his extensive background in academic and industry R&D, Erik brings a unique blend of scientific expertise and commercial acumen to his role. His deep understanding of process development, cGMP contract manufacturing, and recombinant adenoviruses positions him as a key facilitator in advancing innovative vaccine and gene therapy solutions across the European market.

At Advaxia Biologics, Erik is actively involved in identifying and cultivating new business opportunities, aligning client needs with the company’s capabilities in protein biochemistry, viral vector production, and scalable manufacturing processes. His expertise in scientific project leadership, particularly in protein purification, NMR spectroscopy, and cell culture, enables him to effectively communicate complex technical concepts to diverse stakeholders, including biotech partners, regulatory bodies, and industry collaborators. Erik’s proficiency in trade shows, scientific presentations, and leadership further enhances his ability to build meaningful relationships and establish Advaxia as a trusted partner in the biopharmaceutical sector.

Key projects under his purview include expanding Advaxia’s contract manufacturing capacity for recombinant adenoviruses, optimizing process workflows through robotic process automation (RPA), and supporting the development of next-generation biologics. His passion for connecting people and fostering innovative collaborations underscores his commitment to delivering better pharmaceutical products for the future, making him a vital contributor to Advaxia’s mission of advancing life sciences through scientific excellence and strategic partnership.